Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC

In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.

Source: CancerNetwork - April 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news